Hi everyone, Sorry about the late send out this week. In this edition, we cover a range of topics, including the National Institutes of Health's efforts to bolster Long Covid research, the impact of Long Covid on children in the US, and the efficacy of different treatments for Long Covid symptoms.
I would add some caution to the interpretation of the HBOT paper discussed. The original study included sham HBOT as a control group but only short term followup. Patients who received sham were offered HBOT so could not be included in the long term followup for this study. So the only conclusion is that patients who received HBOT felt better a year later, but there could be any number of reasons for this, and difficult to prove it was the HBOT alone that contributed.
"The virus becoming more resistant over time to these antibodies is highly concerning. Do we know if this holds for anti-virals like Paxlovid?"
Let's hope some team of investigators unlocks the virus, not to discover the mechanisms of it's infectiveness or it's virulence but instead understands just how the virus controls its adaptability.. we always assume it's selection pressure combined with sheer numbers combined with high mutagenicity, but is there something more we're missing?
I would add some caution to the interpretation of the HBOT paper discussed. The original study included sham HBOT as a control group but only short term followup. Patients who received sham were offered HBOT so could not be included in the long term followup for this study. So the only conclusion is that patients who received HBOT felt better a year later, but there could be any number of reasons for this, and difficult to prove it was the HBOT alone that contributed.
As always correlation doesn't imply causation.
Good point, Jane!
@Brandon,
I tried to get a paid subscription but it looks like that isn’t an option. Do you know how I can help support this newsletter?
Saw you pledged, thanks! Pledges are still just pledges ( I have not opened them up yet) but I apprecciate the thought.
"The virus becoming more resistant over time to these antibodies is highly concerning. Do we know if this holds for anti-virals like Paxlovid?"
Let's hope some team of investigators unlocks the virus, not to discover the mechanisms of it's infectiveness or it's virulence but instead understands just how the virus controls its adaptability.. we always assume it's selection pressure combined with sheer numbers combined with high mutagenicity, but is there something more we're missing?
Thanks for the shoutout Brandon haha :)